登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 3
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心首都医科大学附属北京朝阳医院Beijing Chao-Yang Hospital北京医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07778316,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 99 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed SCLC with demonstrated progression or relapse.
入选标准第 3 条
Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association > class II) within 6 months prior to first dose of study treatment.
排除标准第 2 条
History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.
排除标准第 3 条
Prior systemic anticancer therapy within 30 days of enrolment
排除标准第 11 条
Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 14 days prior to first dose of study treatment.
排除标准第 13 条
More than 1 prior line of anticancer therapy for SCLC.
排除标准第 16 条
Participation in a tarlatamab clinical trial or prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.
排除标准第 17 条
Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
入选标准第 6 条
Any previous diagnosis of non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation that has transformed to SCLC, or mixed SCLC and NSCLC histology, with exceptions defined in the protocol.
排除标准第 1 条
Measurable disease as defined per RECIST 1.1 within the 21-day screening period.
入选标准第 5 条
History of other malignancy within the past 2 years, with exceptions defined in the protocol.
排除标准第 5 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07778316,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Participant has provided informed consent prior to initiation of any study specific activities/procedures. Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent. Histologically or cytologically confirmed SCLC with demonstrated progression or relapse. Participants who progressed or recurred following 1 platinum-based regimen. Measurable disease as defined per RECIST 1.1 within the 21-day screening period. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1. Minimum life expectancy of 12 weeks. Adequate organ function. History of central nervous system (CNS) metastases are allowed with considerations defined in the protocol.排除标准:Exclusion Criteria:
Any previous diagnosis of non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation that has transformed to SCLC, or mixed SCLC and NSCLC histology, with exceptions defined in the protocol. Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association > class II) within 6 months prior to first dose of study treatment. History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 6 months prior to first dose of study treatment. Current evidence or history of non-infectious pneumonitis/ILD (interstitial lung disease) that required steroids or other immunosuppressive treatment. History of other malignancy within the past 2 years, with exceptions defined in the protocol. Presence or history of viral infection based on criteria per protocol. History of solid organ transplantation. Symptoms and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection requiring antibiotics within 7 days prior to the first dose study treatment. Known sensitivity or a contraindication to any of the products or components. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. Prior systemic anticancer therapy within 30 days of enrolment Prior history of severe or life-threatening events from any immune-mediated therapy. Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 14 days prior to first dose of study treatment. Live and live-attenuated vaccines within 28 days prior to the start of study treatment. Receiving another anticancer therapy for a malignancy other than SCLC. More than 1 prior line of anticancer therapy for SCLC. Participation in a tarlatamab clinical trial or prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway. Treatment in an alternative investigational trial within 28 days prior to enrolment. History of allergy or hypersensitivity to similar products (eg, drugs with a similar chemical structure or other monoclonal antibody) or any excipient. Participants unable to have SC injections administered in the abdomen or thigh. Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements. History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety.
引自 ClinicalTrials.gov, NCT07778316, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07778316,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。